{"id":985734,"date":"2026-07-28T11:05:02","date_gmt":"2026-07-28T15:05:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/podd-shareholder-alert-insulet-corporation-securities-class-action-lawsuit-investors-with-losses-may-contact-suewallst\/"},"modified":"2026-07-28T11:05:02","modified_gmt":"2026-07-28T15:05:02","slug":"podd-shareholder-alert-insulet-corporation-securities-class-action-lawsuit-investors-with-losses-may-contact-suewallst","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/podd-shareholder-alert-insulet-corporation-securities-class-action-lawsuit-investors-with-losses-may-contact-suewallst\/","title":{"rendered":"PODD Shareholder Alert: Insulet Corporation Securities Class Action Lawsuit – Investors With Losses May Contact SueWallSt"},"content":{"rendered":"

\nExecutive Accountability: Eric Benjamin Sold $3.7 Million in Insulet Stock Before Two Medical Device Corrections Allegedly Revealed Previously Undisclosed Manufacturing Deficiencies
\n<\/h2>\n
\n

NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) — SueWallSt notifies investors that Eric Benjamin, Insulet Corporation’s (NASDAQ: PODD) former Executive Vice President and Chief Operating Officer, is named as a defendant in a securities class action alleging he made false statements about Omnipod product safety while selling $3.7 million in company stock during the Class Period.\u00a0Check if you might be eligible to recover your investment losses<\/u><\/a>. You may also contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com<\/u><\/a> or (888) SueWallSt.<\/p>\n

Investors who purchased PODD securities between February 21, 2025 and May 26, 2026 suffered as the stock declined approximately $24 per share cumulatively across the two immediate corrective disclosures that revealed manufacturing issues affecting Omnipod products at Insulet’s Acton, Massachusetts facility. The lead plaintiff deadline is August 31, 2026.<\/p>\n

\n Benjamin’s Role During the Class Period<\/strong>\n <\/p>\n

Eric Benjamin served as Insulet’s Chief Product and Customer Experience Officer from the start of the Class Period through August 25, 2025, when he was promoted to Executive Vice President and Chief Operating Officer.<\/p>\n

During Insulet’s Q2 2025 Earnings Call on August 7, 2025, Benjamin told investors that “Omnipod 5 is safe, effective, understood to be really easy to use,” directly linking the product’s alleged safety profile to accelerating customer conversions. The action contends this statement was materially misleading because Insulet’s manufacturing controls at its Acton facility were already defective, creating a foreseeable risk that Omnipod products would require corrective action.<\/p>\n

\n $3.7 Million in Stock Sales While Safety Claims Continued<\/strong>\n <\/p>\n

The complaint charges that Benjamin sold 12,594 shares of Insulet common stock during the Class Period, collecting approximately $3.7 million in proceeds. These sales represent the largest individual defendant stock dispositions alleged in the case:<\/p>\n